Glycerol phenylbutyrate for the maintenance treatment of patients with deficiencies in enzymes of the urea cycle

References

• Brusilow SW, Horwich AL. Urea cycle enzymes. In: Scriver CRBAL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York (NY): McGraw-Hill; 2001.
   Google Scholar
• Hoffmann GF, Kölker S. Defects in amino acid catabolism and the urea cycle. Handb Clin Neurol. 2013;113:1755–1773.
   Google Scholar
• Batshaw ML. Hyperammonemia. Curr Probl Pediatr. 1984 Nov;14(11):1–69.
   Google Scholar
• Seminara J, Tuchman M, Krivitzky L, et al. Establishing a consortium for the study of rare diseases: the urea cycle disorders consortium. Mol Genet Metab. 2010;100 Suppl 1:S97–105.
   Google Scholar
• Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab. 2013 Sep-Oct;110(1–2):179–180.
   Google Scholar
• Batshaw ML, Tuchman M, Summar M, et al. A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014 Sep-Oct;113(1–2):127–130.
   Google Scholar
• Batshaw ML, Msall M, Beaudet AL, et al. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr. 1986 Feb;108(2):236–241.
   Google Scholar
• Nassogne MC, Héron B, Touati G, et al. Urea cycle defects: management and outcome. J Inherit Metab Dis. 2005;28(3):407–414.
   Google Scholar
• Ruegger CM, Lindner M, Ballhausen D, et al. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. J Inherit Metab Dis. 2014 Jan;37(1):21–30.
   Google Scholar
• Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol. 2002 Feb;7(1):27–35.
   Google Scholar
• Burgard P, Kölker S, Haege G, et al. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders–review and meta-analysis of observational studies published over more than 35 years. J Inherit Metab Dis. 2016 Mar;39(2):219–229.
   Google Scholar
• Summar ML, Dobbelaere D, Brusilow S, et al. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr (Oslo, Norway: 1992). 2008 Oct;97(10):1420–1425.
   Google Scholar
• Diaz GA, Krivitzky LS, Mokhtarani M, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology (Baltimore, MD). 2013 Jun;57(6):2171–2179.
   Google Scholar
• Norenberg MD, Rao KV, Jayakumar AR. Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis. 2005 Dec;20(4):303–318.
   Google Scholar
• Msall M, Monahan PS, Chapanis N, et al. Cognitive development in children with inborn errors of urea synthesis. Acta Paediatr Japon. 1988 Aug;30(4):435–441.
   Google Scholar
• Uchino T, Endo F, Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis. 1998;21 Suppl 1:151–159.
   Google Scholar
• Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr. 2003 Jun;162(6):410–416.
   Google Scholar
• Batshaw ML, Roan Y, Jung AL, et al. Cerebral dysfunction in asymptomatic carriers of ornithine transcarbamylase deficiency. N Engl J Med. 1980;302(9):482–485.
   Google Scholar
• Gyato K, Wray J, Huang ZJ, et al. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann Neurol. 2004 Jan;55(1):80–86.
   Google Scholar
• Krivitzky L, Babikian T, Lee H-S, et al. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res. 2009 Jul;66(1):96–101.
   Google Scholar
• Gropman A. Brain imaging in urea cycle disorders. Mol Genet Metab. 2010;100 Suppl 1:S20–30.
   Google Scholar
• Posset R, Garcia-Cazorla A, Valayannopoulos V, et al. Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. J Inherit Metab Dis. 2016 Sep;39(5):661–672.
   Google Scholar
• Gropman AL, Prust M, Breeden A, et al. Urea cycle defects and hyperammonemia: effects on functional imaging. Metab Brain Dis. 2013 Jun;28(2):269–275.
   Google Scholar
• Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. J Inherit Metab Dis. 2007 Nov;30(6):865–879.
   Google Scholar
• Pacheco-Colón I, Fricke S, VanMeter J, et al. Advances in urea cycle neuroimaging: proceedings from the 4th International Symposium on urea cycle disorders, Barcelona, Spain, September 2013. Mol Genet Metab. 2014 Sep-Oct;113(1–2):118–126.
   Google Scholar
• Gioia GA, Isquith PK, Guy SC. Behavior Rating Inventory of Executive Function. Odessa (FL): Psychological Assessment Resources; 2000.
   Google Scholar
• Harrison P, Oakland T. Adaptive behavior assessment system® - second edition (ABAS® — second edition). San Antonio (TX): Pearson; 2003.
   Google Scholar
• Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012 May;7(1):32.
   Google Scholar
• Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am J Med Genet C Semin Med Genet. 2011 Feb 15;157C(1):45–53.
   Google Scholar
• Nagamani SCS, Erez A, Lee B, et al. Argininosuccinate lyase deficiency. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews(R). Seattle (WA): University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle; 1993. All rights reserved.
   Google Scholar
• Gessler P, Buchal P, Schwenk HU, et al. Favourable long-term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. Eur J Pediatr. 2010 Feb;169(2):197–199.
   Google Scholar
• Batshaw ML, Brusilow S, Waber L, et al. Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med. 1982 Jun 10;306(23):1387–1392.
   Google Scholar
• Brusilow S, Tinker J, Batshaw ML. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science. 1980 Feb 08;207(4431):659–661.
   Google Scholar
• Brusilow SW, Valle DL, Batshaw M. New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet. 1979 Sep 01;2(8140):452–454.
   Google Scholar
• Mistry PK. Rare disease clinical research network’s urea cycle consortium delivers a successful clinical trial to improve alternate pathway therapy. Hepatology (Baltimore, Md). 2013 Jun;57(6):2100–2102.
   Google Scholar
• Nagamani SC, Diaz GA, Rhead W, et al. Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials. Mol Genet Metab. 2015 Sep-Oct;116(1–2):29–34.
   Google Scholar
• Shchelochkov OA, Dickinson K, Scharschmidt BF, et al. Barriers to drug adherence in the treatment of urea cycle disorders: assessment of patient, caregiver and provider perspectives. Mol Genetics Metab Rep. 2016 Sep;8:43–47.
   Google Scholar
• Monteleone JP, Mokhtarani M, Diaz GA, et al. Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders. J Clin Pharmacol. 2013 Jul;53(7):699–710.
   Google Scholar
• Cederbaum S, Lemons C, Batshaw ML. Alternative pathway or diversion therapy for urea cycle disorders now and in the future. Mol Genet Metab. 2010 Jul;100(3):219–220.
   Google Scholar
• Ravicti [package insert]. Lake Forest (IL): Horizon Therapeutics; 2017 April.
   Google Scholar
• Lee B, Rhead W, Diaz GA, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab. 2010 Jul;100(3):221–228.
   Google Scholar
• Lichter-Konecki U, Diaz GA, Merritt JL 2nd, et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab. 2011 Aug;103(4):323–329.
   Google Scholar
• Smith W, Ga D, Lichter-Konecki U, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr. 2013 Jun;162(6):1228–1234, 34.e1.
   Google Scholar
• Berry SA, Lichter-Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes. Mol Genet Metab. 2014 May;112(1):17–24.
   Google Scholar
• Berry SA, Longo N, Diaz GA, et al. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2 months to 2 years. Mol Genet Metab. 2017 Sep 8. pii: S1096-7192(17)30491-2. doi: 10.1016/j.ymgme.2017.09.002. [Epub ahead of print].
   Google Scholar
• Kent JD, Holt RJ. Hyperammonemic crises in patients with urea cycle disorders on chronic nitrogen scavenger therapy with either sodium phenylbutyrate or glycerol phenylbutyrate. Neuropsychiatry (London). 2017;7(2):131–136.
   Google Scholar
• Lee B, Diaz GA, Rhead W, et al. Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder. Genet Med. 2015 Jul;17(7):561–568.
   Google Scholar
• McGuire BM, Zupanets IA, Lowe ME, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology (Baltimore, Md). 2010 Jun;51(6):2077–2085.
   Google Scholar
• Mokhtarani M, Diaz GA, Rhead W, et al. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. Mol Genet Metab. 2012 Nov;107(3):308–314.
   Google Scholar
• Hook D, Diaz GA, Lee B, et al. Protein and calorie intakes in adult and pediatric subjects with urea cycle disorders participating in clinical trials of glycerol phenylbutyrate. Mol Genetics Metab Rep. 2016 Mar;6:34–40.
   Google Scholar
• Thibault A, Cooper MR, Figg WD, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 1994 Apr 01;54(7):1690–1694.
   Google Scholar
• Thibault A, Samid D, Cooper MR, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 1995 Jun 15;75(12):2932–2938.
   Google Scholar
• Mokhtarani M, Diaz GA, Rhead W, et al. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol Genet Metab. 2013 Dec;110(4):446–453.
   Google Scholar
• European Medicines Agency Ravicti Assessment Report. 2015. [cited 2017 Nov 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003822/WC500199159.pdf.
   Google Scholar
• Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res. 1991 Feb;29(2):147–150.
   Google Scholar
• McGuire PJ, Lee H-S; Members of the Urea Cycle Disorders Consortium, Summar ML. Infectious precipitants of acute hyperammonemia are associated with indicators of increased morbidity in patients with urea cycle disorders. J Pediatr. 2013 Dec;163(6):1705–1710.e1.
   Google Scholar
• Wilson D, Bressani R, Scrimshaw NS. Infection and nutritional status. I. The effect of chicken pox on nitrogen metabolism in children. Am J Clin Nutr. 1961 Mar-Apr;9:154–158.
   Google Scholar
• Mokhtarani M, Diaz GA, Lichter-Konecki U, et al. Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate. Mol Genetics Metab Rep. 2015 Dec;5:12–14.
   Google Scholar
• Lee B, Diaz GA, Rhead W, et al. Glutamine and hyperammonemic crises in patients with urea cycle disorders. Mol Genet Metab. 2016 Jan;117(1):27–32.
   Google Scholar
• Burrage LC, Jain M, Gandolfo L, et al. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. Mol Genet Metab. 2014 Sep-Oct;113(1–2):131–135.
   Google Scholar
• Scaglia F, Carter S, O’Brien WE, et al. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab. 2004 Apr;81(Suppl 1):S79–85.
   Google Scholar
• Paxton R, Harris RA. Clofibric acid, phenylpyruvate, and dichloroacetate inhibition of branched-chain alpha-ketoacid dehydrogenase kinase in vitro and in perfused rat heart. Arch Biochem Biophys. 1984 May 15;231(1):58–66.
   Google Scholar
• Marini JC, Lanpher BC, Scaglia F, et al. Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients. Am J Clin Nutr. 2011 Jun;93(6):1248–1254.
   Google Scholar
• Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med. 1996 Sep 19;335(12):855–859.
   Google Scholar
• Maestri NE, Hauser ER, Bartholomew D, et al. Prospective treatment of urea cycle disorders. J Pediatr. 1991 Dec;119(6):923–928.
   Google Scholar